AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. RAPT
  4. [Form 4] RAPT Therapeutics, Inc. Insider Trading Activity

[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

RAPT Therapeutics Chief Medical Officer William Ho received a new stock option grant on June 20, 2025. The derivative securities transaction details include:

  • Grant of 75,000 employee stock options
  • Exercise price set at $7.43 per share
  • Options expire on June 19, 2035
  • Vesting schedule: 1/48th of shares vest monthly from June 20, 2025

This Form 4 filing, signed by attorney-in-fact Rodney Young, represents a standard equity compensation grant to a key executive officer. The ten-year option grant suggests a long-term retention strategy for the Chief Medical Officer position. The monthly vesting schedule over four years aligns with typical industry practices for executive compensation.

Il Chief Medical Officer di RAPT Therapeutics, William Ho, ha ricevuto una nuova concessione di opzioni su azioni il 20 giugno 2025. I dettagli della transazione sui titoli derivati sono i seguenti:

  • Concessione di 75.000 opzioni azionarie per dipendenti
  • Prezzo di esercizio fissato a 7,43 $ per azione
  • Le opzioni scadono il 19 giugno 2035
  • Programma di maturazione: 1/48 delle azioni matura mensilmente a partire dal 20 giugno 2025

Questa comunicazione Form 4, firmata dal procuratore Rodney Young, rappresenta una concessione standard di compensazione azionaria a un dirigente chiave. La durata decennale dell鈥檕pzione suggerisce una strategia di fidelizzazione a lungo termine per la posizione di Chief Medical Officer. Il piano di maturazione mensile su quattro anni 猫 in linea con le consuete pratiche del settore per la retribuzione degli executive.

El Director M茅dico de RAPT Therapeutics, William Ho, recibi贸 una nueva concesi贸n de opciones sobre acciones el 20 de junio de 2025. Los detalles de la transacci贸n de valores derivados incluyen:

  • Concesi贸n de 75,000 opciones sobre acciones para empleados
  • Precio de ejercicio establecido en $7.43 por acci贸n
  • Las opciones expiran el 19 de junio de 2035
  • Calendario de adquisici贸n: 1/48 de las acciones se adquiere mensualmente desde el 20 de junio de 2025

Este formulario 4, firmado por el apoderado Rodney Young, representa una concesi贸n est谩ndar de compensaci贸n en acciones a un ejecutivo clave. La concesi贸n de opciones a diez a帽os sugiere una estrategia de retenci贸n a largo plazo para el puesto de Director M茅dico. El calendario de adquisici贸n mensual durante cuatro a帽os se alinea con las pr谩cticas habituales de la industria para la compensaci贸n ejecutiva.

RAPT Therapeutics鞚� 斓滉碃 鞚橂 毂呾瀯鞛� William Ho电� 2025雲� 6鞗� 20鞚�鞐� 靸堧鞖� 鞀ろ啞 鞓奠厴鞚� 攵�鞐皼鞎橃姷雼堧嫟. 韺岇儩 歃濌秾 瓯半灅 靹鸽秬 靷暛鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 歆侅洂 鞀ろ啞 鞓奠厴 75,000欤� 攵�鞐�
  • 頄夓偓臧�瓴╈潃 欤茧嫻 $7.43搿� 靹れ爼
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 19鞚�
  • 氩犾姢韺� 鞚检爼: 2025雲� 6鞗� 20鞚茧秬韯� 毵れ洈 1/48鞌� 氩犾姢韺�

氤� Form 4 鞝滌稖 靹滊电� 雽�毽澑 Rodney Young鞚� 靹滊獏頄堨溂氅�, 頃奠嫭 鞛勳洂鞐� 雽�頃� 響滌 欤检嫕 氤挫儊 攵�鞐ゼ 雮橅儉雰呺媹雼�. 10雲勱皠鞚� 鞓奠厴 攵�鞐鐢 斓滉碃 鞚橂 毂呾瀯鞛� 歆侅眳鞐� 雽�頃� 鞛リ赴 鞙犾 鞝勲灥鞚� 鞁滌偓頃╇媹雼�. 4雲勱皠 毵れ洈 氩犾姢韺� 鞚检爼鞚� 鞛勳洂 氤挫儊鞐� 雽�頃� 鞐呹硠 鞚茧皹 甏�頄夑臣 鞚检箻頃╇媹雼�.

Le directeur m茅dical de RAPT Therapeutics, William Ho, a re莽u une nouvelle attribution d鈥檕ptions d鈥檃chat d鈥檃ctions le 20 juin 2025. Les d茅tails de la transaction sur titres d茅riv茅s sont les suivants :

  • Attribution de 75 000 options d鈥檃chat d鈥檃ctions aux employ茅s
  • Prix d鈥檈xercice fix茅 脿 7,43 $ par action
  • Expiration des options le 19 juin 2035
  • Calendrier d鈥檃cquisition : 1/48 des actions acquises mensuellement 脿 partir du 20 juin 2025

Ce d茅p么t Formulaire 4, sign茅 par le mandataire Rodney Young, repr茅sente une attribution standard de r茅mun茅ration en actions 脿 un cadre cl茅. L鈥檃ttribution d鈥檕ptions sur dix ans sugg猫re une strat茅gie de r茅tention 脿 long terme pour le poste de directeur m茅dical. Le calendrier d鈥檃cquisition mensuel sur quatre ans est conforme aux pratiques habituelles de l鈥檌ndustrie en mati猫re de r茅mun茅ration des cadres.

Der Chief Medical Officer von RAPT Therapeutics, William Ho, erhielt am 20. Juni 2025 eine neue Aktienoptionszuteilung. Die Details der Transaktion mit derivativen Wertpapieren umfassen:

  • Gew盲hrung von 75.000 Mitarbeiteraktienoptionen
  • Aus眉bungspreis von 7,43 $ pro Aktie
  • Optionen laufen am 19. Juni 2035 ab
  • Vesting-Zeitplan: 1/48 der Aktien wird monatlich ab dem 20. Juni 2025 freigegeben

Diese Form 4-Meldung, unterzeichnet vom Bevollm盲chtigten Rodney Young, stellt eine standardm盲脽ige Aktienverg眉tung f眉r einen wichtigen F眉hrungskraft dar. Die zehnj盲hrige Optionslaufzeit deutet auf eine langfristige Bindungsstrategie f眉r die Position des Chief Medical Officer hin. Der monatliche Vesting-Zeitplan 眉ber vier Jahre entspricht den 眉blichen Branchenpraktiken f眉r die Verg眉tung von F眉hrungskr盲ften.

Positive
  • None.
Negative
  • None.

Il Chief Medical Officer di RAPT Therapeutics, William Ho, ha ricevuto una nuova concessione di opzioni su azioni il 20 giugno 2025. I dettagli della transazione sui titoli derivati sono i seguenti:

  • Concessione di 75.000 opzioni azionarie per dipendenti
  • Prezzo di esercizio fissato a 7,43 $ per azione
  • Le opzioni scadono il 19 giugno 2035
  • Programma di maturazione: 1/48 delle azioni matura mensilmente a partire dal 20 giugno 2025

Questa comunicazione Form 4, firmata dal procuratore Rodney Young, rappresenta una concessione standard di compensazione azionaria a un dirigente chiave. La durata decennale dell鈥檕pzione suggerisce una strategia di fidelizzazione a lungo termine per la posizione di Chief Medical Officer. Il piano di maturazione mensile su quattro anni 猫 in linea con le consuete pratiche del settore per la retribuzione degli executive.

El Director M茅dico de RAPT Therapeutics, William Ho, recibi贸 una nueva concesi贸n de opciones sobre acciones el 20 de junio de 2025. Los detalles de la transacci贸n de valores derivados incluyen:

  • Concesi贸n de 75,000 opciones sobre acciones para empleados
  • Precio de ejercicio establecido en $7.43 por acci贸n
  • Las opciones expiran el 19 de junio de 2035
  • Calendario de adquisici贸n: 1/48 de las acciones se adquiere mensualmente desde el 20 de junio de 2025

Este formulario 4, firmado por el apoderado Rodney Young, representa una concesi贸n est谩ndar de compensaci贸n en acciones a un ejecutivo clave. La concesi贸n de opciones a diez a帽os sugiere una estrategia de retenci贸n a largo plazo para el puesto de Director M茅dico. El calendario de adquisici贸n mensual durante cuatro a帽os se alinea con las pr谩cticas habituales de la industria para la compensaci贸n ejecutiva.

RAPT Therapeutics鞚� 斓滉碃 鞚橂 毂呾瀯鞛� William Ho电� 2025雲� 6鞗� 20鞚�鞐� 靸堧鞖� 鞀ろ啞 鞓奠厴鞚� 攵�鞐皼鞎橃姷雼堧嫟. 韺岇儩 歃濌秾 瓯半灅 靹鸽秬 靷暛鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:

  • 歆侅洂 鞀ろ啞 鞓奠厴 75,000欤� 攵�鞐�
  • 頄夓偓臧�瓴╈潃 欤茧嫻 $7.43搿� 靹れ爼
  • 鞓奠厴 毵岆鞚检潃 2035雲� 6鞗� 19鞚�
  • 氩犾姢韺� 鞚检爼: 2025雲� 6鞗� 20鞚茧秬韯� 毵れ洈 1/48鞌� 氩犾姢韺�

氤� Form 4 鞝滌稖 靹滊电� 雽�毽澑 Rodney Young鞚� 靹滊獏頄堨溂氅�, 頃奠嫭 鞛勳洂鞐� 雽�頃� 響滌 欤检嫕 氤挫儊 攵�鞐ゼ 雮橅儉雰呺媹雼�. 10雲勱皠鞚� 鞓奠厴 攵�鞐鐢 斓滉碃 鞚橂 毂呾瀯鞛� 歆侅眳鞐� 雽�頃� 鞛リ赴 鞙犾 鞝勲灥鞚� 鞁滌偓頃╇媹雼�. 4雲勱皠 毵れ洈 氩犾姢韺� 鞚检爼鞚� 鞛勳洂 氤挫儊鞐� 雽�頃� 鞐呹硠 鞚茧皹 甏�頄夑臣 鞚检箻頃╇媹雼�.

Le directeur m茅dical de RAPT Therapeutics, William Ho, a re莽u une nouvelle attribution d鈥檕ptions d鈥檃chat d鈥檃ctions le 20 juin 2025. Les d茅tails de la transaction sur titres d茅riv茅s sont les suivants :

  • Attribution de 75 000 options d鈥檃chat d鈥檃ctions aux employ茅s
  • Prix d鈥檈xercice fix茅 脿 7,43 $ par action
  • Expiration des options le 19 juin 2035
  • Calendrier d鈥檃cquisition : 1/48 des actions acquises mensuellement 脿 partir du 20 juin 2025

Ce d茅p么t Formulaire 4, sign茅 par le mandataire Rodney Young, repr茅sente une attribution standard de r茅mun茅ration en actions 脿 un cadre cl茅. L鈥檃ttribution d鈥檕ptions sur dix ans sugg猫re une strat茅gie de r茅tention 脿 long terme pour le poste de directeur m茅dical. Le calendrier d鈥檃cquisition mensuel sur quatre ans est conforme aux pratiques habituelles de l鈥檌ndustrie en mati猫re de r茅mun茅ration des cadres.

Der Chief Medical Officer von RAPT Therapeutics, William Ho, erhielt am 20. Juni 2025 eine neue Aktienoptionszuteilung. Die Details der Transaktion mit derivativen Wertpapieren umfassen:

  • Gew盲hrung von 75.000 Mitarbeiteraktienoptionen
  • Aus眉bungspreis von 7,43 $ pro Aktie
  • Optionen laufen am 19. Juni 2035 ab
  • Vesting-Zeitplan: 1/48 der Aktien wird monatlich ab dem 20. Juni 2025 freigegeben

Diese Form 4-Meldung, unterzeichnet vom Bevollm盲chtigten Rodney Young, stellt eine standardm盲脽ige Aktienverg眉tung f眉r einen wichtigen F眉hrungskraft dar. Die zehnj盲hrige Optionslaufzeit deutet auf eine langfristige Bindungsstrategie f眉r die Position des Chief Medical Officer hin. Der monatliche Vesting-Zeitplan 眉ber vier Jahre entspricht den 眉blichen Branchenpraktiken f眉r die Verg眉tung von F眉hrungskr盲ften.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
HO WILLIAM
(Last) (First) (Middle)
C/O RAPT THERAPEUTICS, INC.
561 ECCLES AVENUE
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
RAPT Therapeutics, Inc. [ RAPT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF MEDICAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $7.43 06/20/2025 A 75,000 (1) 06/19/2035 Common Stock 75,000 $0 75,000 D
Explanation of Responses:
1. 1/48th of the shares subject to the option shall vest on each monthly anniversary of the vesting commencement date of June 20, 2025.
/s/ Rodney Young, Attorney-in-Fact 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What stock options were granted to RAPT Therapeutics' Chief Medical Officer William Ho in June 2025?

William Ho was granted 75,000 employee stock options on June 20, 2025, with an exercise price of $7.43 per share. These options expire on June 19, 2035.

What is the vesting schedule for William Ho's RAPT stock options granted in June 2025?

The stock options vest monthly over 4 years, with 1/48th of the shares vesting each month following the vesting commencement date of June 20, 2025.

Who filed the Form 4 for RAPT Therapeutics (RAPT) on June 28, 2025?

The Form 4 was filed for William Ho, RAPT Therapeutics' Chief Medical Officer, and was signed by Rodney Young as Attorney-in-Fact on June 24, 2025.

What is the total value of RAPT stock options granted to William Ho in June 2025?

William Ho received options to purchase 75,000 shares of RAPT common stock at an exercise price of $7.43 per share. The options were granted at $0 cost to Ho as part of his compensation package.
Stock RAPT logo
Rapt Therapeutics, Inc.

NASDAQ:RAPT

RAPT Rankings

#6028 Ranked by Market Cap
N/A Ranked by Dividends

RAPT Latest News

Jun 23, 2025
RAPT Therapeutics Names Two Industry Veterans to its Board of Directors
Jun 13, 2025
RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split
Jun 4, 2025
RAPT Therapeutics to Participate in Upcoming Investor Conferences
May 8, 2025
RAPT Therapeutics Reports First Quarter 2025 Financial Results
Apr 15, 2025
RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of聽Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

RAPT Latest SEC Filings

Jun 30, 2025
[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity
Jun 30, 2025
[Form 3] RAPT Therapeutics, Inc. Initial Statement of Beneficial Ownership
Jun 24, 2025
[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity
Jun 24, 2025
[Form 3] RAPT Therapeutics, Inc. Initial Statement of Beneficial Ownership
Jun 24, 2025
[Form 4] RAPT Therapeutics, Inc. Insider Trading Activity

RAPT Stock Data

135.93M
12.71M
0.49%
96.43%
1.99%
Biotechnology
Pharmaceutical Preparations
United States
SOUTH SAN FRANCISCO